meta|Evidence - COVID-19
click on circles to display study description...
chloroquine and derivatives (n=6) vs. placebo (n=4)
randomized controlled trial high risk of bias
chloroquine 150 mg/day for 8 weeks
placebo
infections other than COVID-19
double-blind
Iran
chloroquine and derivatives (n=63) vs. placebo (n=66)
randomized controlled trial some concerns about risk of bias
chloroquine 600 mg/day for three days
placebo
infections other than COVID-19
Brazil
chloroquine and derivatives (n=757) vs. placebo (n=749)
randomized controlled trial low risk of bias
chloroquine
chloroquine phosphate (500 mg/day for 1 week, then once a week to complete 12 weeks)
placebo
infections other than COVID-19
double-blind
Singapore
chloroquine and derivatives (n=278) vs. placebo (n=276)
randomized controlled trial low risk of bias
600 mg D1-2, 300 mg D3
placebo
infections other than COVID-19
double-blind
Viet Nam
chloroquine and derivatives (n=27) vs. placebo (n=27)
randomized controlled trial high risk of bias
chloroquine
chloroquine 600 mg at day 1, 600 mg at days 2 and 3, and 300 mg at days 4 and 5
placebo
infections other than COVID-19
double-blind
French Reunion Island
convalescent plasma treatment (n=42) vs. control (n=45)
randomized controlled trial some concerns about risk of bias
anti-influenza plasma
two units (or paediatric equivalent) of anti-influenza plasma with haemagglutination inhibition antibody titres of 1:80 or more
standard care
infections other than COVID-19
open-label
29 academic medical centres in the USA
convalescent plasma treatment (n=92) vs. placebo (n=48)
randomized controlled trial low risk of bias
anti-influenza plasma
high-titre anti-influenza plasma (haemagglutination inhibition antibody titre ≥1:80)
low-titre plasma
low-titre plasma (≤1:10)
infections other than COVID-19
double-blind
41 US medical centres
convalescent plasma treatment (n=-9) vs. placebo (n=-9)
randomized controlled trial some concerns about risk of bias
anti-influenza hyperimmune intravenous immunoglobulin (hIVIG)
standard care plus a single 500-mL infusion of high-titre hIVIG (0·25 g/kg bodyweight, 24·75 g maximum; hIVIG group)
placebo
saline placebo
infections other than COVID-19
double-blind
not in intention to treat
convalescent plasma treatment (n=17) vs. placebo (n=18)
randomized controlled trial some concerns about risk of bias
hyperimmune IV immunoglobulin treatment
convalescent plasma from patients who recovered from the 2009 pandemic influenza A(H1N1) (A[H1N1]) infection, fractionated to hyperimmune IV immunoglobulin (H-IVIG) by CSL biotherapies (now bioCSL)
placebo
normal IV immunoglobulin manufactured before 2009 as control
infections other than COVID-19
double-blind
face mask (n=569) vs. control (n=458)
cluster randomized trial some concerns about risk of bias
cloth masks
control
3 arms: cloth mask; medical masks and control
infections other than COVID-19
open-label
14 secondary-level/tertiary-level hospitals in Hanoi, Vietnam.
face mask (n=580) vs. control (n=458)
cluster randomized trial risk of bias NA
medical masks
control
3 arms: cloth mask; medical masks and control
infections other than COVID-19
open-label
14 secondary-level/tertiary-level hospitals in Hanoi, Vietnam.
powered by vis.js Network